4.120USD-1.32%Mkt Cap: 261.56M USDP/E: —Last update: 2026-06-01
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pip…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap261.56M USD
Enterprise Value146.70M USD
Revenue (TTM)157.08M USD
Gross Profit113.49M USD
Net Income (TTM)-74.62M USD
Revenue/Share2.482 USD
Last Price4.120 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees293
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS5560991094
Valuation
P/E (Trailing)—
P/E (Forward)-2.94
PEG—
EV/EBITDA-2.59
EV/Revenue0.93
P/S1.68
P/B12.46
EPS (TTM)-1.11
EPS (Forward)-1.41
52W Range
1.18585% of range4.640
52W High4.640 USD
52W Low1.185 USD
Profitability
Gross Margin75.91%
Oper. Margin-160.96%
EBITDA Margin-36.01%
Profit Margin-49.91%
ROE-134.23%
ROA-29.05%
Growth
Revenue Growth57.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.04M USD
CapEx (TTM)1.91M USD
FCF Margin7.54%
FCF Yield4.53%
Net Debt-117.72M USD
Net Debt/EBITDA2.08
Balance Sheet
Debt/Equity0.66
Current Ratio1.90
Quick Ratio1.72
Book Value/Sh0.3340 USD
Cash/Share2.426 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)6.750 USD
Target Range4.000 USD – 9.000 USD
# Analysts4
Ownership
Shares Out.63.56M
Float55.60M
Insiders3.43%
Institutions70.24%
Short Interest
Short Ratio3.9d
Short % Float7.95%
Short % Out.7.67%
Shares Short4.88M
Short (prev mo.)2.93M
Technical
SMA 503.408 (+20.9%)
SMA 2002.151 (+91.5%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)1.17M
Avg Vol (10d)1.37M
Technical Indicators
RSI (14)59.8
MACD0.3182
MACD Signal0.2971
MACD Hist.+0.0211
BB Upper5.061 USD
BB Middle3.804 USD
BB Lower2.546 USD
BB Width66.14%
ATR (14)0.2826 USD
Vol Ratio (20d)0.15x